# A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

> **NCT07169851** · PHASE2 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 204 (estimated)

## Conditions studied

- Nausea
- Vomiting
- Drug-Related Side Effects and Adverse Reactions
- Neoplasms

## Interventions

- **DRUG:** LY3537021
- **DRUG:** Placebo
- **DRUG:** Standard of Care Antiemetic Therapies
- **DRUG:** Background Chemotherapy

## Key facts

- **NCT ID:** NCT07169851
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2026-12
- **Final completion:** 2027-02
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169851, "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07169851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*